Format

Send to

Choose Destination
Blood Rev. 2014 Nov;28(6):235-41. doi: 10.1016/j.blre.2014.07.005. Epub 2014 Aug 24.

The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates.

Author information

1
Service d'hématologie, CHUV, Rue du Bugnon 26, 1011 Lausanne, Switzerland. Electronic address: julie.kaiser@chuv.ch.
2
Service régional vaudois de transfusion, Route de la Corniche 2, 1066 Epalinges, Switzerland. Electronic address: giorgia.canellini@mavietonsang.ch.
3
Service régional vaudois de transfusion, Route de la Corniche 2, 1066 Epalinges, Switzerland. Electronic address: niels.lion@mavietonsang.ch.
4
Service régional vaudois de transfusion, Route de la Corniche 2, 1066 Epalinges, Switzerland. Electronic address: melanie.abonnenc@mavietonsang.ch.
5
Service régional vaudois de transfusion, Route de la Corniche 2, 1066 Epalinges, Switzerland. Electronic address: jean-claude.osselaer@mavietonsang.ch.
6
Service régional vaudois de transfusion, Route de la Corniche 2, 1066 Epalinges, Switzerland. Electronic address: jean-daniel.tissot@mavietonsang.ch.

Abstract

Since 1990, several techniques have been developed to photochemically inactivate pathogens in platelet concentrates, potentially leading to safer transfusion therapy. The three most common methods are amotosalen/UVA (INTERCEPT Blood System), riboflavin/UVA-UVB (MIRASOL PRT), and UVC (Theraflex-UV). We review the biology of pathogen inactivation methods, present their efficacy in reducing pathogens, discuss their impact on the functional aspects of treated platelets, and review clinical studies showing the clinical efficiency of the pathogen inactivation methods and their possible toxicity.

KEYWORDS:

Amotosalen; Hemovigilance; Pathogen inactivation; Pathogen reduction; Platelet concentrates; Platelets; Riboflavin; Transfusion

PMID:
25192602
DOI:
10.1016/j.blre.2014.07.005
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center